Luchetti MM, Benfaremo D, Ciccia F, Bolognini L, Ciferri M, Farinelli A, Rossini M, Mosca P, Triolo G, Gabrielli A. Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study. World J Gastroenterol 2017; 23(39): 7139-7149 [PMID: 29093622 DOI: 10.3748/wjg.v23.i39.7139]
Corresponding Author of This Article
Michele Maria Luchetti, MD, Dipartimento Scienze Cliniche e Molecolari, Clinica Medica, Università Politecnica delle Marche, Ancona 60126, Italy. m.luchetti@univpm.it
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Luchetti MM, Benfaremo D, Ciccia F, Bolognini L, Ciferri M, Farinelli A, Rossini M, Mosca P, Triolo G, Gabrielli A. Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study. World J Gastroenterol 2017; 23(39): 7139-7149 [PMID: 29093622 DOI: 10.3748/wjg.v23.i39.7139]
World J Gastroenterol. Oct 21, 2017; 23(39): 7139-7149 Published online Oct 21, 2017. doi: 10.3748/wjg.v23.i39.7139
Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study
Michele Maria Luchetti, Devis Benfaremo, Francesco Ciccia, Laura Bolognini, Monia Ciferri, Alessia Farinelli, Matteo Rossini, Piergiorgio Mosca, Giovanni Triolo, Armando Gabrielli
Michele Maria Luchetti, Devis Benfaremo, Monia Ciferri, Alessia Farinelli, Matteo Rossini, Armando Gabrielli, Dipartimento Scienze Cliniche e Molecolari, Clinica Medica, Università Politecnica delle Marche, Ancona 60126, Italy
Francesco Ciccia, Giovanni Triolo, Dipartimento Biomedico di Medicina Interna e Specialistica, Sezione di Reumatologia, Università degli Studi di Palermo, Palermo 90021, Italy
Laura Bolognini, Piergiorgio Mosca, Dipartimento Gastroenterologico e dei Trapianti, Polo Ospedaliero-Universitario “Umberto I-G.M. Lancisi- G. Salesi”, Ancona 60126, Italy
Author contributions: Luchetti MM and Benfaremo D contributed equally to this work; Luchetti MM, Benfaremo D and Ciccia F contributed to study conception and design, data analysis and interpretation, and writing of the article; Benfaremo D, Bolognini L, Ciferri M, Farinelli A, Rossini M and Mosca P contributed to data acquisition; Luchetti MM, Benfaremo D, Ciccia F, Triolo G and Gabrielli A contributed to editing, reviewing and final approval of article.
Institutional review board statement: The study was reviewed and approved by the Comitato Etico, Polo Ospedaliero-Universitaria “Umberto I-G.M. Lancisi-G. Salesi”, Ancona, Italy, according to the 2015 local and national procedural laws.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: No additional data are available.
Correspondence to: Michele Maria Luchetti, MD, Dipartimento Scienze Cliniche e Molecolari, Clinica Medica, Università Politecnica delle Marche, Ancona 60126, Italy. m.luchetti@univpm.it
Telephone: +39-71-2206101 Fax: +39-71-2206103
Received: May 28, 2017 Peer-review started: April 1, 2017 First decision: June 5, 2017 Revised: July 6, 2017 Accepted: August 15, 2017 Article in press: August 15, 2017 Published online: October 21, 2017 Processing time: 206 Days and 11.9 Hours
Core Tip
Core tip: Enteropathic spondyloarthritis (ES) is characterized by articular inflammation in patients with inflammatory bowel diseases, such as Crohn’s disease or ulcerative colitis. Correct management, especially covering both of the two clinical manifestations (gastro-rheumatologic), remains a challenge. In this study, we demonstrated that the integrated gastroenterological and rheumatologic evaluation of ES patients achieved the best therapeutic approach. In particular, we demonstrated that in a real-life cohort of ES patients, the tumor necrosis factor-inhibitor, adalimumab, led to fast and sustained improvement of articular and gastrointestinal inflammation, with a consequent improvement in the global and gastrointestinal quality of life.
